<DOC>
	<DOCNO>NCT00857805</DOCNO>
	<brief_summary>Patients liver tumor burden exceed Milan criterion consider receive one follow locoregional treatment : transarterial chemoembolization ( TACE ) , radiofrequency ablation ( RFA ) , percutaneous ethanol injection proton beam radiation ( PBR ) . The goal treatment control tumor growth , downstage tumor size meet Milan criterion , improve survival . Patients exceed Milan criterion benefit tumor downstaging result treatment . Patients meet Milan criterion benefit tumor control bridge liver transplantation . TACE consider common locoregional treatment use treat hepatocellular carcinoma ( HCC ) . Proton beam radiotherapy use treat HCC center across globe . Phase I II trial show satisfactory safety efficacy result . Loma Linda University Medical Center one pioneering center use proton beam treatment HCC . This first randomize trial medical field compare head-to-head efficacy TACE versus proton beam treat HCC patient .</brief_summary>
	<brief_title>Transarterial Chemoembolization Versus Proton Beam Radiotherapy Treatment Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Patients candidate receive proton beam TACE 2 . Patients evidence metastasis macrovascular invasion 3 . Patients tumor burden meet San Francisco criteria 1 . Patients candidate surgical resection 2 . Patients lesion &lt; 2 cm 3 . Patients contraindication receive either TACE proton 4 . Patients serum alpha fetoprotein &gt; 500 5 . Patients metastasis macrovascular invasion 6 . Patients treat previously HCC locoregional treatment 7 . Patients prior liver transplant 8 . Patients Child class C 9 . Patients MELD score &gt; 25 10 . Patients comorbid disease may impact survival 11 . Patients ongoing alcohol intake 12 . Patients active sepsis 13 . Patients gastrointestinal bleeding within week 14 . Patients unwilling sign inform consent form 15 . Patients history noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Transarterial chemoembolization</keyword>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Proton Beam Radiotherapy</keyword>
</DOC>